EUVIMEDEUVIMED entdecken
Crossref

FDA approved fezolinetant (Veozah): a critical evaluation of its efficacy and safety for menopausal vasomotor symptoms, calling for prospective research

Priya Rani, Dua Zehra, Malaika Mansoor, Payal Rani

Archives of Women's Mental Health · 2024

DOI: 10.1007/s00737-024-01456-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Women's Mental Health, 2024. Verfasst von Priya Rani und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Ziauddin University, Karachi, Pakistan. Hauptthemen laut MEDLINE: Hot Flashes, Menopause. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Women going through menopause frequently experience vasomotor symptoms such as hot flashes, night sweats, and sleep disturbances, significantly influencing their quality of life. Hormonal therapy has been demonstrated to be beneficial in treating VMS. However, due to specific restrictions, it is not recommended for every woman. Fezolinetant, a neurokinin 3 antagonist and non-hormonal treatment for severe to moderate VMS, functions by inhibiting neuronal impulses originating from the hypothalamic thermoregulatory center. Current Skylight 2 and 4 trials statistically demonstrate the safety and acceptability of fezolinetant, with relatively few adverse effects reported. Fezolinetant has been shown great potential for treating menopausal-related VMS, supporting its further advancement. However, further investigation is required to thoroughly evaluate its safety, effectiveness, and its impact on sleep patterns.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hot FlashesMenopauseFemaleHumansMiddle AgedDrug ApprovalQuality of LifeTreatment OutcomeUnited StatesUnited States Food and Drug Administration

Stichwörter der Autor:innen

FDA approvedFezolinetantHot flashesMenopauseNight sweatsVasomotor symptoms

Autor:innen und Institutionen

  • Department of Internal Medicine, Ziauddin University, Karachi, Pakistan.
  • Department of Internal Medicine, Jinnah Sindh Medical University, Karachi, Pakistan.
  • Department of Internal Medicine, Karachi Medical and Dental University, Karachi, Pakistan.
  • Department of Internal Medicine, Dow University of Health Sciences, Baba-e-Urdu Road, Karachi, Pakistan. doultanipayal2002@gmail.com.

Zitieren

APA

Rani, P., Zehra, D., Mansoor, M., & Rani, P. (2024). FDA approved fezolinetant (Veozah): a critical evaluation of its efficacy and safety for menopausal vasomotor symptoms, calling for prospective research. Archives of Women's Mental Health. https://doi.org/10.1007/s00737-024-01456-y

Vancouver

Rani P, Zehra D, Mansoor M, Rani P. FDA approved fezolinetant (Veozah): a critical evaluation of its efficacy and safety for menopausal vasomotor symptoms, calling for prospective research. Archives of Women's Mental Health. 2024. doi:10.1007/s00737-024-01456-y

BibTeX
@article{Rani2024,
  author = {Rani, Priya and Zehra, Dua and Mansoor, Malaika and Rani, Payal},
  title = {FDA approved fezolinetant (Veozah): a critical evaluation of its efficacy and safety for menopausal vasomotor symptoms, calling for prospective research},
  journal = {Archives of Women's Mental Health},
  year = {2024},
  doi = {10.1007/s00737-024-01456-y}
}
Kostenlos starten →